|
1
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2015. CA Cancer J Clin. 65:5–29. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Prat J: Ovarian carcinomas: Five distinct
diseases with different origins, genetic alterations, and
clinicopathological features. Virchows Arch. 460:237–249. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Yan C, Jiang Y, Wan Y, Zhang L, Liu J,
Zhou S and Cheng W: Long noncoding RNA NBAT-1 suppresses
tumorigenesis and predicts favorable prognosis in ovarian cancer.
Onco Targets Ther. 10:1993–2002. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jacobs AS, Schwartz MD, Valdimarsdottir H,
Nusbaum RH, Hooker GW, DeMarco TA, Heinzmann JE, McKinnon W,
McCormick SR, Davis C, et al: Patient and genetic counselor
perceptions of in-person versus telephone genetic counseling for
hereditary breast/ovarian cancer. Fam Cancer. 15:529–539. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ganeshan D, Bhosale P, Wei W, Ramalingam
P, Mudasiru- Dawodu E, Gershenson D, Sun C and Iyer R: Increase in
post-therapy tumor calcification on CT scan is not an indicator of
response to therapy in low-grade serous ovarian cancer. Abdom
Radiol (NY). 41:1589–1595. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hoppenot C, Eckert MA, Tienda SM and
Lengyel E: Who are the long-term survivors of high grade serous
ovarian cancer? Gynecol Oncol. 148:204–212. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hacker KE, Uppal S and Johnston C:
Principles of treatment for borderline, micropapillary serous, and
low-grade ovarian cancer. J Natl Compr Canc Netw. 14:1175–1182.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shih Ie M and Kurman RJ: Ovarian
tumorigenesis: A proposed model based on morphological and
molecular genetic analysis. Am J Surg Pathol. 164:1511–1518. 2004.
View Article : Google Scholar
|
|
10
|
Khalique L, Ayhan A, Weale ME, Jacobs IJ,
Ramus SJ and Gayther SA: Genetic intra-tumour heterogeneity in
epithelial ovarian cancer and its implications for molecular
diagnosis of tumours. J Pathol. 211:286–295. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chow YP, Alias H and Jamal R:
Meta-analysis of gene expression in relapsed childhood B-acute
lymphoblastic leukemia. BMC Cancer. 17:1202017. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ding Y, Yang DZ, Zhai YN, Xue K, Xu F, Gu
XY and Wang SM: Microarray expression profiling of long non-coding
RNAs in epithelial ovarian cancer. Oncol Lett. 14:2523–2530. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Wang H, Fu Z, Dai C, Cao J, Liu X, Xu J,
Lv M, Gu Y, Zhang J, Hua X, et al: LncRNAs expression profiling in
normal ovary, benign ovarian cyst and malignant epithelial ovarian
cancer. Sci Rep. 6:389832016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Mateescu B, Batista L, Cardon M, Gruosso
T, de Feraudy Y, Mariani O, Nicolas A, Meyniel JP, Cottu P,
Sastre-Garau X and Mechta-Grigoriou F: miR-141 and miR-200a act on
ovarian tumorigenesis by controlling oxidative stress response. Nat
Med. 17:1627–1635. 2011. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Lisowska KM, Olbryt M, Dudaladava V,
Pamula-Pilat J, Kujawa K, Grzybowska E, Jarzab M, Student S,
Rzepecka IK, Jarzab B and Kupryjańczyk J: Gene expression analysis
in ovarian cancer-faults and hints from DNA microarray study. Front
Oncol. 4:62014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ferriss JS, Kim Y, Duska L, Birrer M,
Levine DA, Moskaluk C, Theodorescu D and Lee JK: Multi-gene
expression predictors of single drug responses to adjuvant
chemotherapy in ovarian carcinoma: Predicting platinum resistance.
PLoS One. 7:e305502012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Tothill RW, Tinker AV, George J, Brown R,
Fox SB, Lade S, Johnson DS, Trivett MK, Etemadmoghadam D, Locandro
B, et al: Novel molecular subtypes of serous and endometrioid
ovarian cancer linked to clinical outcome. Clin Cancer Res.
14:5198–5208. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Taminau J, Meganck S, Lazar C, Steenhoff
D, Coletta A, Molter C, Duque R, de Schaetzen V, Weiss Solis DY,
Bersini H and Nowé A: Unlocking the potential of publicly available
microarray data using inSilicoDb and inSilicoMerging R/Bioconductor
packages. BMC Bioinformatics. 13:3352012. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Hong F, Breitling R, McEntee CW, Wittner
BS, Nemhauser JL and Chory J: RankProd: A bioconductor package for
detecting differentially expressed genes in meta-analysis.
Bioinformatics. 22:2825–2827. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Huang da W, Sherman BT and Lempicki RA:
Systematic and integrative analysis of large gene lists using DAVID
bioinformatics resources. Nat Protoc. 4:44–57. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Ito K and Murphy D: Application of ggplot2
to Pharmacometric Graphics. CPT Pharmacometrics Syst Pharmacol.
2:e792013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Chan SK, Griffith OL, Tai IT and Jones SJ:
Meta-analysis of colorectal cancer gene expression profiling
studies identifies consistently reported candidate biomarkers.
Cancer Epidemiol Biomarkers Prev. 17:543–552. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Botling J, Edlund K, Lohr M, Hellwig B,
Holmberg L, Lambe M, Berglund A, Ekman S, Bergqvist M, Ponten F, et
al: Biomarker discovery in non-small cell lung cancer: Integrating
gene expression profiling, meta-analysis, and tissue microarray
validation. Clin Cancer Res. 19:194–204. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Goonesekere NC, Wang X, Ludwig L and Guda
C: A meta analysis of pancreatic microarray datasets yields new
targets as cancer genes and biomarkers. PLoS One. 9:e930462014.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Singh G, Roy J, Rout P and Mallick B:
Genome-wide profiling of the PIWI-interacting RNA-mRNA regulatory
networks in epithelial ovarian cancers. PLoS One. 13:e01904852018.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shi C and Zhang Z: Screening of
potentially crucial genes and regulatory factors involved in
epithelial ovarian cancer using microarray analysis. Oncol Lett.
14:725–732. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Januchowski R, Sterzynska K, Zawierucha P,
Rucinski M, Swierczewska M, Partyka M, Bednarek-Rajewska K, Brazert
M, Nowicki M, Zabel M, et al: Microarray-based detection and
expression analysis of new genes associated with drug resistance in
ovarian cancer cell lines. Oncotarget. 8:49944–49958. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wei S, Liu J, Shi Y, Zhang X, Yang Y and
Song Q: Exploration of the sequential gene changes in epithelial
ovarian cancer induced by carboplatin via microarray analysis. Mol
Med Rep. 16:3155–3160. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
He J, Huang Y, Liu Z, Zhao R, Liu Q, Wei
L, Yu X, Li B and Qin Y: Hypomethylation of BORIS is a promising
prognostic biomarker in hepatocellular carcinoma. Gene. 629:29–34.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Martin-Kleiner I: BORIS in human cancers-a
review. Eur J Cancer. 48:929–935. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
D'Arcy V, Pore N, Docquier F, Abdullaev
ZK, Chernukhin I, Kita GX, Rai S, Smart M, Farrar D, Pack S, et al:
BORIS, a paralogue of the transcription factor, CTCF, is aberrantly
expressed in breast tumours. Br J Cancer. 98:571–579. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kang Y, Hong JA, Chen GA, Nguyen DM and
Schrump DS: Dynamic transcriptional regulatory complexes including
BORIS, CTCF and Sp1 modulate NY-ESO-1 expression in lung cancer
cells. Oncogene. 26:4394–4403. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Risinger JI, Chandramouli GV, Maxwell GL,
Custer M, Pack S, Loukinov D, Aprelikova O, Litzi T, Schrump DS,
Murphy SK, et al: Global expression analysis of cancer/testis genes
in uterine cancers reveals a high incidence of BORIS expression.
Clin Cancer Res. 13:1713–1719. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Hoffmann MJ, Muller M, Engers R and Schulz
WA: Epigenetic control of CTCFL/BORIS and OCT4 expression in
urogenital malignancies. Biochem Pharmacol. 72:1577–1588. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Woloszynska-Read A, James SR, Link PA, Yu
J, Odunsi K and Karpf AR: DNA methylation-dependent regulation of
BORIS/CTCFL expression in ovarian cancer. Cancer Immun.
7:212007.PubMed/NCBI
|
|
37
|
Link PA, Zhang W, Odunsi K and Karpf AR:
BORIS/CTCFL mRNA isoform expression and epigenetic regulation in
epithelial ovarian cancer. Cancer Immun. 13:62013.PubMed/NCBI
|
|
38
|
Woloszynska-Read A, Zhang W, Yu J, Link
PA, Mhawech-Fauceglia P, Collamat G, Akers SN, Ostler KR, Godley
LA, Odunsi K and Karpf AR: Coordinated cancer germline antigen
promoter and global DNA hypomethylation in ovarian cancer:
Association with the BORIS/CTCF expression ratio and advanced
stage. Clin Cancer Res. 17:2170–2180. 2011. View Article : Google Scholar : PubMed/NCBI
|
